Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9

被引:10
作者
Taylor, Ronald P. [1 ,8 ]
Lindorfer, Margaret A. [1 ,8 ]
Cook, Erika M. [1 ,8 ]
Beurskens, Frank J. [2 ]
Schuurman, Janine [2 ]
Parren, Paul W. H. I. [2 ,3 ,9 ]
Zent, Clive S. [4 ]
VanDerMeid, Karl R. [4 ]
Burack, Richard [5 ]
Mizuno, Masashi [6 ]
Morgan, B. Paul [7 ,10 ]
机构
[1] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22903 USA
[2] Genmab, NL-3584 CM Utrecht, Netherlands
[3] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands
[4] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14627 USA
[5] Univ Rochester, Med Ctr, Pathol Dept, Rochester, NY 14627 USA
[6] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan
[7] Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, S Glam, Wales
[8] Univ Virginia, Sch Med, Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA
[9] Leiden Univ, Med Ctr, NL-2333 ZA Leiden, Netherlands
[10] Cardiff Univ, Sch Med, Cardiff CF14 4XN, S Glam, Wales
关键词
Complement; Immunotherapy; Monoclonal antibodies; CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-LYSIS; IN-VITRO; RITUXIMAB; HEXAMERS; CD59;
D O I
10.1016/j.clim.2017.05.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We examined complement-dependent cytotoxicity (CDC) by hexamer formation-enhanced CD20 mAb Hx-7D8 of patient-derived chronic lymphocytic leukemia (CLL) cells that are relatively resistant to CDC. CDC was analyzed in normal human serum (NHS) and serum from an individual genetically deficient for C9. Hx-7D8 was able to kill up to 80% of CLL cells in complete absence of C9. We conclude that the narrow C5b-8 pores formed without C9 are sufficient for CDC due to efficient antibody-mediated hexamer formation. In the absence of C9, we observed transient intracellular increases of Ca2+ during CDC (as assessed with FLUO-4) that were extended in time. This suggests that small C5b-8 pores allow Ca2+ to enter the cell, while dissipation of the fluorescent signal accompanying cell disintegration is delayed. The Ca2+ signal is retained concomitantly with TOPRO-3 (viability dye) staining, thereby confirming that Ca2+ influx represents the most proximate mediator of cell death by CDC. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 13 条
  • [1] Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation
    Hayashi, Kazumi
    Nagasaki, Eijiro
    Kan, Shin
    Ito, Masaki
    Kamata, Yuko
    Homma, Sadamu
    Aiba, Keisuke
    CANCER SCIENCE, 2016, 107 (05): : 682 - 689
  • [2] An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity
    Wirt, Tim
    Rosskopf, Sophia
    Rosner, Thies
    Eichholz, Klara Marie
    Kahrs, Anne
    Lutz, Sebastian
    Kretschmer, Anna
    Valerius, Thomas
    Klausz, Katja
    Otte, Anna
    Gramatzki, Martin
    Peipp, Matthias
    Kellner, Christian
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (05) : 292 - 300
  • [3] An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels
    Roesner, Thies
    Derer, Stefanie
    Kellner, Christian
    Dechant, Michael
    Lohse, Stefan
    Vidarsson, Gestur
    Peipp, Matthias
    Valerius, Thomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (02) : 282 - 286
  • [4] Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity
    Winiarska, Magdalena
    Nowis, Dominika
    Bil, Jacek
    Glodkowska-Mrowka, Eliza
    Muchowicz, Angelika
    Wanczyk, Malgorzata
    Bojarczuk, Kamil
    Dwojak, Michal
    Firczuk, Malgorzata
    Wilczek, Ewa
    Wachowska, Malgorzata
    Roszczenko, Katarzyna
    Miaczynska, Marta
    Chlebowska, Justyna
    Basak, Grzegorz Wladyslaw
    Golab, Jakub
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (38) : 31983 - 31993
  • [5] Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
    Bil, Jacek
    Winiarska, Magdalena
    Nowis, Dominika
    Bojarczuk, Kamil
    Dabrowska-Iwanicka, Anna
    Basak, Grzegorz W.
    Sulek, Kazimierz
    Jakobisiak, Marek
    Golab, Jakub
    BLOOD, 2010, 115 (18) : 3745 - 3755
  • [6] Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies
    Prantl, Lena
    Heider, Philipp
    Bergmeister, Lisa
    Calana, Katharina
    Bohn, Jan-Paul
    Wolf, Dominik
    Banki, Zoltan
    Bosch, Andreas
    Plach, Maximilian
    Huber, Georg
    Schroedel, Silke
    Thirion, Christian
    Stoiber, Heribert
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
    GazzanoSantoro, H
    Ralph, P
    Ryskamp, TC
    Chen, AB
    Mukku, VR
    JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 202 (02) : 163 - 171
  • [8] The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
    Kuzniewska, Alicja
    Majeranowski, Alan
    Henry, Sara
    Kowalska, Daria
    Stasilojc, Grzegorz
    Urban, Aleksandra
    Zaucha, Jan M.
    Okroj, Marcin
    CANCERS, 2024, 16 (01)
  • [9] CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
    Lindorfer, Margaret A.
    Beum, Paul V.
    Taylor, Ronald P.
    ANTIBODIES, 2013, 2 (04): : 598 - 616
  • [10] An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab
    Gasdaska, John R.
    Sherwood, Steven
    Regan, Jeffrey T.
    Dickey, Lynn F.
    MOLECULAR IMMUNOLOGY, 2012, 50 (03) : 134 - 141